Introduction {#S0001}
============

Gastric cancer, one of the most common malignant tumours after lung cancer and liver cancer, occurs in the upper digestive tract.[@CIT0001],[@CIT0002] Approximately 20% of gastric cancer patients are diagnosed with peritoneal metastasis before surgery.[@CIT0003] More than half of advanced gastric cancer patients have peritoneal metastasis after surgery, which leads to poor prognosis.[@CIT0003] The 5-year survival rate of patients with positive peritoneal lavage cytology is approximately 12%, and the median survival time of patients with peritoneal metastasis is approximately 6--7 months.[@CIT0004],[@CIT0005] However, the sensitivity of gastric cancer peritoneal metastasis imaging and tumour marker detection is low. Therefore, the need to find sensitive diagnostic markers of gastric cancer with peritoneal metastasis is urgent.

Metabolomics can accurately discover the basic characteristics and material basis of life activities.[@CIT0006]--[@CIT0010] It can enlarge small changes in the genome and proteome, reflecting the endpoint of gene functional activities and changes in the biochemical phenotype of organisms, and is also directly related to the final effect of these activities.[@CIT0011] Therefore, metabolomics is considered the final direction of omics research.[@CIT0012] Yue et al[@CIT0013] found 43 arginine metabolites helpful for the accurate diagnosis of small cell lung cancer by LC-MS. Zhang et al[@CIT0014] found that the levels of 9 metabolites, such as glutamic acid and glutamine, were significantly different in the cancerous tissues and normal tissues of 40 patients with oesophageal squamous cell carcinoma by LC-MS and that this difference was closely related to the pathological characteristics of lymph node metastasis and postoperative survival time. However, the application of metabolomics to peritoneal metastasis of gastric cancer is still unclear.

In this study, we collected the PLF of 65 gastric cancer patients and related clinical data from the First Hospital of Jilin University. The metabolic components of the PLF were determined by LC-MS. TIC spectra, PCA, and the *t*-test were used to identify differential metabolites in PLF samples. An SVM was used to screen the differential metabolites with a weight of 100%. Cluster analysis was used to evaluate the similarity between samples. ROC analysis was used to assess the diagnostic ability of the metabolites. Univariate and multivariate logistic regression analyses were used to identify potential risk factors for peritoneal metastasis in gastric cancer patients. We found the differential levels of PLF metabolites by LC-MS, TIC spectra, PCA and the *t*-test. Cluster analysis showed the co-occurrence of metabolites in the peritoneal metastasis group. ROC analysis showed the diagnostic ability of metabolites. Univariate and multivariate logistic regression analyses showed the potential independent risk factors for peritoneal metastasis in gastric cancer patients. In the end, we found that TG (54:2), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methylalanine, sulfite, CL (63:4), PE-NMe (40:5), TG (53:4), retinol, 3-hydroxysterol, tetradecanoic acid, MG (21:0/0:0/0:0), tridecanoic acid, myristate glycine and octacosanoic acid may be biomarkers for peritoneal metastasis of gastric cancer.

Patients and Methods {#S0002}
====================

Patient Source and Sample Collection {#S0002-S2001}
------------------------------------

From August 2018 to December 2018, 62 patients with gastric cancer (45 males and 17 females) underwent laparoscopic exploration or laparoscopic radical gastrectomy. Informed consent was obtained from patients and their families before surgery, and the study was approved by the Ethics Committee of The First Hospital of Jilin University, together with confirmation of patient written informed consent, and compliance with the Declaration of Helsinki. The inclusion criteria for patients with gastric cancer were as follows: samples obtained from the First Hospital of Jilin University; a pathological diagnosis of gastric cancer; an age of no more than 75 years; the presence of primary tumours; good liver function, heart function, renal function and bone marrow function; and no other serious immunosuppressive diseases or simultaneous malignant tumours. The exclusion criteria for patients with gastric cancer were as follows: congenital diseases; poor general condition; severe organic diseases; previous radical or palliative surgery, radiotherapy, chemotherapy or biotherapy; complications of gastrointestinal haemorrhage; perforation; and serious infection.

Two hundred millilitres of lavage fluid were collected from the subphrenic space, subhepatic space and Douglas fossa of 62 patients with gastric cancer.

Exfoliative Cytology {#S0002-S2002}
--------------------

After centrifugation, the supernatants of PLF samples from 62 gastric cancer patients were discarded, and the precipitates were retained. After smearing, the exfoliative cytology was detected by pasteurization.

qRT-PCR {#S0002-S2003}
-------

The total RNA was extracted from the PLF samples by TRIzol™ reagent (Invitrogen Thermo Science) and then reverse transcribed to produce cDNA. Finally, the cDNA was amplified by PCR. [Table 1](#T0001){ref-type="table"} lists the sequences of the primers used. We used TransStart TIP Green qPCR SuperMix (cat. No. AQ131, TransGen Biotech Co., Ltd., Beijing, China) for RT qPCR analysis. The analysis mixture contained 0.2 g of DNA, 0.2 M forward primers, 0.2 M reverse primers, and 10 μL of qPCR SuperMix in a total volume of 20 µL. The conditions were as follows: 94.0°C for 30 seconds, followed by 40 cycles of 94.0°C for 5 seconds and 60.0°C for 30 seconds. Three replicates of each sample were analysed in a CFX 96 Touch Real-time Polymerase Chain Reaction Detection System (Bio-Rad Laboratory Ltd.). The relative expression of actin and CEA in the different experimental groups was calculated by the 2-ΔΔCq method.Table 1CEA mRNA Results of Peritoneal LavageInvasion of SerosaNo Invasion of SerosaTotalCEA Positive16925CEA Negative82937Total243862

LC-MS {#S0002-S2004}
-----

Four microliters of each sample were chromatographed onto a C18 reverse-phase column (2.1 × 100 mm, 1.8 μm, Waters, Milford, MA) using an Agilent 1290 Infinity liquid chromatography system (Agilent, Santa Clara, CA). During chromatographic separation, the column was maintained at 40°C. Elution was performed at a flow rate of 400 μL/min, with 5% acetonitrile in water for the first 2 min, a linear gradient of 5% to 95% acetonitrile over the next 15 min, and 95% acetonitrile in water for the last 2 min. Both acetonitrile and water contained 0.1% formic acid.

Statistical Analysis {#S0002-S2005}
--------------------

The *t*-test was carried out to analyse the positive ion mode and negative ion mode data, and differential metabolites were screened by *p*\<0.05. An SVM was used to precisely identify different metabolites. The BRB array tool was used for cluster analysis to uncover the distributions of poorly metabolised foreign bodies in patients with gastric cancer.[@CIT0015] ROC curves were drawn with SPSS based on a series of different binary classifications (demarcation value or determination threshold) as well as the true-positive rate (sensitivity), the ordinate and the false-positive rate (1-specificity) according to the abscissa. Univariate and multivariate logistic regression analyses were used in SPSS to identify risk factors for peritoneal metastasis of gastric cancer.

Results {#S0003}
=======

Different Levels of Metabolites in the PLF of Gastric Cancer Patients {#S0003-S2001}
---------------------------------------------------------------------

According to the pathological data, the patients were divided into two groups. Patients in group A had serous invasion, and those in group B did not have serous invasion. According to the results of exfoliative cytology of the PLF, findings during surgery and pathological data, a group positive for peritoneal metastasis (group C) and a group negative for peritoneal metastasis of gastric cancer (group D) were found. According to qRT-PCR analysis of CEA mRNA in PLF, patients were divided into a CEA-positive group (group E) and a CEA-negative group (group F; [Table 1](#T0001){ref-type="table"}).

Mass spectral data of the metabolites were obtained by LC-MS. Moreover, we found a difference in the expression of metabolites between groups A and B, groups C and D, and groups E and F by the TIC spectra ([Figure 1](#F0001){ref-type="fig"}). Differences in the levels of metabolites between groups A and B, groups C and group D, and groups E and group F were further verified by PCA ([Figure 2](#F0002){ref-type="fig"}).Figure 1TIC spectra of the different groups. TIC analysis of groups A and B (**A** and **B**), groups C and D (**C** and **D**), and groups E and F (**E** and **F**).Figure 2PCA of the different groups. PCA of groups A and B (**A** and **B**), groups C and D (**C** and **D**), and groups E and F (**E** and **F**).

The results of a *t*-test to analyse data in positive and negative ion mode found 213 differential metabolites in positive ion mode ([[supplemental material Table 1](https://www.dovepress.com/get_supplementary_file.php?f=245663.docx)]{.ul}) and 174 differential metabolites in negative ion mode between groups A and B ([[supplemental material Table 2](https://www.dovepress.com/get_supplementary_file.php?f=245663.docx)]{.ul}). In addition, 190 differential metabolites ([[supplemental material Table 3](https://www.dovepress.com/get_supplementary_file.php?f=245663.docx)]{.ul}) between groups C and D were screened under cation mode, and 115 differential metabolites ([[supplemental material Table 4](https://www.dovepress.com/get_supplementary_file.php?f=245663.docx)]{.ul}) were screened in negative ion mode. Screening of groups E and F revealed 501 differential metabolites in positive ion mode ([[supplemental material Table 5](https://www.dovepress.com/get_supplementary_file.php?f=245663.docx)]{.ul}) and 246 differential metabolites in negative ion mode ([[supplemental material Table 6](https://www.dovepress.com/get_supplementary_file.php?f=245663.docx)]{.ul}).

Differential Metabolites in the PLF of Patients with Peritoneal Metastasis Screened with a Weight of 100% {#S0003-S2002}
---------------------------------------------------------------------------------------------------------

We used an SVM to carry out discrimination analysis to distinguish the patients in each group and further screened differential metabolites with a weight of 100%. Four differential metabolites in positive ion mode and 4 differential metabolites in negative ion mode were identified between groups A and B ([Table 2](#T0002){ref-type="table"}). Two differential metabolites in positive ion mode and 2 differential metabolites in negative ion mode were identified between groups C and D ([Table 3](#T0003){ref-type="table"}). Ten differential metabolites in positive ion mode and 4 differential metabolites in negative ion mode were identified between groups E and F ([Table 4](#T0004){ref-type="table"}). The mass to charge ratios (M/Z) were used to screen the human metabolome database (HMDB) to find the corresponding substances. The differential metabolites between groups A and B were sulfite, TG (54:2), G3P, α-aminobutyric acid, α-CEHC, dodecanol, alanine glutamyl, and 3-methylpropionic acid ([Table 2](#T0002){ref-type="table"}). The differential metabolites between groups C and D were sulfite, G3P, Cl (63:4), and PE-NMe (40:5) ([Table 3](#T0003){ref-type="table"}). The differential metabolites between groups E and F were sulfite, G3P, TG (54:2), α-aminobutyric acid, α-CEHC, glutamyl alanine, retinol, 3-hydroxysterol, tetradecanoic acid, MG (21:0/0:0/0:0), tridecanoic acid, myristate glycine, octadecanoic acid, and TG (53:4) ([Table 4](#T0004){ref-type="table"}).Table 2Groups A and B Screened Out Different MetabolitesDifferential SubstanceMass Charge Ratio (m/z)Retention Time*p*Group A ResponsivenessGroup B ResponsivenessWeightSulfite116.928216.238.46E-05151.6±20.7120.6±32100%TG (54:2)289.93718.622.19E-11397.6±94.1238.8±58.6100%G3P190.928919.981.32E-09232.2±49104.6±78100%α - aminobutyric acid181.897916.275.76E-1371.6±17.229.6±17.9100%α-CEHC279.15934.653.75E-061324.9±630.9725.7±287.6100%dodecanol228.23268.033.42E-061411.6±354.91008.1±264.5100%Glutamyl alanine302.14475.446.12E-131805.8±369.9903±385.4100%3-methylpropionic acid106.989916.159.49E-101220.3±471.9437.6±374100% Table 3Groups C and D Screened Out Different MetabolitesDifferential SubstanceMass Charge Ratio (m/z)Retention Time*p*Group C ResponsivenessGroup D ResponsivenessWeightCL(63:4)685.437916.10.0005845.2±339219.1±361.1100%PE-NMe(40:5)808.58539.750.000453907.2±2355.3535±534.3100%Sulfite116.928216.262.38E-06683.7±70.3365.2±156.1100%G3P190.928919.981.72E-07235.9±43.372.5±54.9100% Table 4Groups E and F Screened Out Different MetabolitesDifferential SubstanceMass Charge Ratio (m/z)Retention Time*p*Group E ResponsivenessGroup F ResponsivenessWeightSulfite116.928216.263.05E-21698.8±83.6310±115.2100%G3P190.928919.983.12E-22197.2±36.659±34.2100%TG(54:2)289.93718.623.03E-13316.2±73161.1±58100%α - aminobutyric acid181.897916.275.88E-1472.9±16.728.5±18.2100%TG(53:4)476.41276.133.61E-10181.3±56.762.3±64.3100%Alpha-CEHC279.15934.651.45E-151724.8±444.2723.9±292.1100%Glutamyl alanine302.14475.445.36E-121935.8±224.81064.5±472.9100%Retinal596.44888.813.78E-11105.4±4726.1±30.5100%3-hydroxysterol432.38756.071.21E-09568.5±162.9233.8±190.3100%Tetradecenoic acid268.22667.091.42E-09276.4±87132.7±70.9100%MG(21:0/0:0/0:0)242.21155.761.54E-09875.1±212.3501.6±195.7100%Tridecanoic acid214.21747.541.16E-09690.6±180.2390.5±147100%Myristoyl glycine308.22027.095.15E-10372.8±112.3179.1±92.9100%Octadecanoic acid254.2484.62.27E-10510.1±93.2337.2±83.9100%

Cluster analysis showed the co-occurrence of metabolites in groups A, C and E. As shown in [Figure 3](#F0003){ref-type="fig"}, the levels of TG (54:2), sulfite, G3P, α-aminobutyric acid, α-CEHC, glutamyl alanine and 3-methylpropionic acid in group A were similar. In addition, the levels of CL (63:1), PE-NMe (10:5), sulfite and G3P in group C were similar. The levels of sulfite, TG (54:2), G3P, α-aminobutyric acid, pyrite, TG (53:4), retinal, α-CEHC, 3-hydroxysterol, tetradecanoic acid, Mg (21:0/0:0/0:0), tridecanoic acid, and octadecanoic acid in group E were similar.Figure 3Cluster analysis of the different groups. Cluster analysis of groups A and B (**A**), groups C and D (**B**), and groups E and F (**C**).

Differential Metabolites Have Good Diagnostic Ability for Peritoneal Metastasis in Gastric Cancer Patients {#S0003-S2003}
----------------------------------------------------------------------------------------------------------

ROC analysis showed that sulfite, TG (54:2), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine and 3-methylalanine had good diagnostic ability in groups A and B ([Table 5](#T0005){ref-type="table"}; [Figure 4](#F0004){ref-type="fig"}). In groups C and D, sulfite, G3P, Cl (63:4), and PE-NMe (40:5) had good diagnostic ability ([Table 6](#T0006){ref-type="table"}; [Figure 4](#F0004){ref-type="fig"}). In groups E and F, sulfite, G3P, TG (54:2), α-aminobutyric acid, TG (53:4), α-CEHC, glutamyl alanine, retinol, 3-hydroxysterol, tetradecanoic acid, MG (21:0/0:0/0:0), tridecanoic acid, myristate glycine and octacosanoic acid had good diagnostic ability ([Table 7](#T0007){ref-type="table"}; [Figure 4](#F0004){ref-type="fig"}).Table 5Area Under ROC Curve of Differential Metabolites in Groups A and BDifferential MetabolitesAreaStandard ErrorSig.95% CILowerUpperSulfite0.7820.0600.6640.899TG(54:2)0.7420.0720.0010.6010.884G3P0.8790.04400.7940.965α - aminobutyric acid0.9550.02900.8971Alpha-CEHC0.7860.06200.6650.907Decylene0.8060.05900.690.922Glutamyl alanine0.9560.02300.91113-methylpropionic acid0.8680.0500.7710.966 Table 6Area Under ROC Curve of Differential Metabolites in Groups C and DDifferential MetabolitesAreaStandard ErrorSig.95% CILowerUpperSulfite0.9060.090.0020.731G3P0.9830.02200.9391CL (63:4)0.850.1010.0060.6531PE-NMe(40:5)0.9830.02200.941 Table 7Area Under ROC Curve of Differential Metabolites in Groups E and FDifferential MetabolitesAreaStandard ErrorSig.95% CILowerUpperSulfite0.8590.04800.7650.954G3P0.8740.04600.7840.963TG(54:2)0.9490.02500.9010.997α - aminobutyric acid0.9630.02800.9091TG(53:4)0.9090.03700.8370.981Alpha-CEHC0.9640.0200.9241Glutamyl alanine0.9680.02400.921Retinal0.9130.0400.8350.993-hydroxysterol0.9020.03800.8270.976Tetradecenoic acid0.9040.03700.8310.977MG(21:0/0:0/0:0)0.8990.0400.8220.977Tridecanoic acid0.9090.03600.8380.98Myristoyl glycine0.9040.03800.830.978Octadecanoic acid0.9050.03800.830.98 Figure 4ROC curve analysis of metabolites in the different groups. ROC curve analysis of differential metabolites between groups A and B (**A**), groups C and D (**B**), and groups E and F (**C**).

Metabolites are Independent Risk Factors for Peritoneal Metastasis in Gastric Cancer Patients {#S0003-S2004}
---------------------------------------------------------------------------------------------

Univariate regression analysis showed that sulfite, TG (54:2), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine and 3-methylpropionic acid were risk factors for peritoneal metastasis of gastric cancer in groups A and B ([Table 8](#T0008){ref-type="table"}). Sulfite, G3P, Cl (63:4), and PE-NMe (40:5) were risk factors for peritoneal metastasis of gastric cancer in groups C and D ([Table 9](#T0009){ref-type="table"}). Sulfite, glyceraldehyde 3-phosphate, TG (54:2), α-aminobutyric acid, TG (53:4), α-CEHC, glutamyl alanine, retinol, 3-hydroxysterol, tetradecanoic acid, Mg (21:0/0:0/0:0), tridecanoic acid, myristate glycine and octacosanoic acid were risk factors for peritoneal metastasis of gastric cancer in groups E and F ([Table 10](#T0010){ref-type="table"}).Table 8Univariate Logistic Regression for Group A and Group BDifferential MetabolitesBS.E.Wals*p*95% CILowerUpperSulfite0.0430.01310.8450.0010.0031.762TG (54:2)0.0090.00310.4910.0010.4581.078G3P0.0230.00616.78800.1212.233α - aminobutyric acid0.1050.02418.90800.0892.231Alpha-CEHC0.0030.00112.34400.2122.234Dodecanol0.0040.00113.70901.0021.007Glutamyl alanine0.0070.00212.93400.9893.3453-hydroxysterol0.0030.00119.93700.5022.992 Table 9Univariate Logistic Regression for Group C and Group DDifferential MetabolitesBS.E.Wals*p*95% CILowerUpperCL(63:4)0.0040.0027.230.0070.8951.546PE-NMe(40:5)0.0030.0024.6280.0310.9892.345Sulfite0.0150.0057.3330.0070.5021.992G3P0.0550.0322.910.0880.3252.445 Table 10Univariate Logistic Regression for Group E and Group FDifferential MetabolitesBS.E.Wals*p*95% CILowerUpperSulfite0.0090.00214.18300.3252.445G3P0.0560.01416.81200.6232.762TG (54:2)0.0320.00816.28800.8951.546α - aminobutyric acid0.1040.02419.29300.9892.345TG(53:4)0.0270.00617.91900.5021.992Alpha-CEHC0.0060.00212.78800.3252.445Glutamyl alanine0.0110.00310.3240.0010.8891.231Retinal0.0470.01117.71801.0012.2333-hydroxysterol0.0090.00217.27900.9831.078Tetradecenoic acid0.0220.00517.06801.0121.234MG(21:0/0:0/0:0)0.0080.00217.6600.0012.233Tridecanoic acid0.0110.00317.06300.5021.992Myristoyl glycine0.0160.00418.13700.9251.445Octadecanoic acid0.020.00516.75700.0881.078

Multivariate regression analysis showed that sulfite, TG (54:2), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine and 3-methylalanine were independent risk factors for peritoneal metastasis of gastric cancer in groups A and B ([Table 11](#T0011){ref-type="table"}). Sulfite, CL (63:4), and PE-NMe (40:5) were independent risk factors for peritoneal metastasis of gastric cancer in groups C and D ([Table 12](#T0012){ref-type="table"}). Sulfite, G3P, TG (54:2), α-aminobutyric acid, TG (53:4), α-CEHC, glutamyl alanine, retinol, 3-hydroxysterol, tetradecanoic acid, MG (21:0/0:0/0:0), tridecanoic acid, myristate glycine and octacosanoic acid were independent risk factors for peritoneal metastasis of gastric cancer in groups E and F ([Table 13](#T0013){ref-type="table"}).Table 11Multivariate Logistic Regression of Group A and Group BDifferential MetabolitesBS.E.Wals*p*95% CILowerUpperSulfite0.2871.6392.2270.0080.5233.762TG (54:2)−0.4720.5493.00100.0081.078G3P0.2060.7360.04502.0015.233α - aminobutyric acid0.9790.4470.1020.0051.0894.231Alpha-CEHC0.3190.1551.1120.0092.3444.234Dodecanol0.9530.4243.22105.2348.23Glutamyl alanine0.4140.5732.87400.9892.3453-hydroxysterol−0.4970.5810.02200.5021.992 Table 12Multivariate Logistic Regression of Group C and Group DDifferential MetabolitesBS.E.Wals*p*95% CILowerUpperCL(63:4)0.0159.0057.3330.0070.6232.762PE-NMe(40:5)−7.5963.1675.7520.01600.078Sulfite0.1564.1988.3420.0071.0012.233 Table 13Multivariate Logistic Regression of Group E and Group FDifferential MetabolitesBS.E.Wals*p*95% CILowerUpperSulfite0.011.25930.51800.5021.992G3P0.0427.65121.01200.9251.445TG (54:2)0.0642.85932.24200.0881.078α-aminobutyric acid0.673.24214.1660.0091.0012.233TG(53:4)0.0521.15224.37900.8891.231Alpha-CEHC0.0142.24821.5901.0121.234Glutamyl alanine0.0015.44723.23400.8951.546Retinal0.1526.39422.08400.9892.3453-hydroxysterol−0.0432.5223.5500.5021.992Tetradecenoic acid−0.0991.84421.23800.3252.445MG(21:0/0:0/0:0)−0.0723.51813.68200.6231.762Tridecanoic acid0.0181.01230.98600.9832.078Myristoyl glycine0.1170.24322.12301.0012.233Octadecanoic acid0.0514.97926.14700.8021.992

Discussion {#S0004}
==========

Gastric cancer, which has a high incidence and poor prognosis, seriously threatens human health.[@CIT0002],[@CIT0016],[@CIT0017] Peritoneal metastasis is an important factor in the death of gastric cancer patients. Most patients diagnosed with peritoneal metastasis of gastric cancer have already had cancerous ascites and metastasis and lost the opportunity for treatment.[@CIT0018],[@CIT0019] However, there are no obvious symptoms or signs of the early stage of peritoneal metastasis of gastric cancer, and conventional ultrasound, CT and other detection methods cannot diagnose peritoneal metastasis precisely. Therefore, the need to find more sensitive diagnostic markers for peritoneal metastasis of gastric cancer is urgent. Compared with some single molecular markers, metabolic diagnostic markers are more comprehensive and accurate.[@CIT0020]--[@CIT0033] Metabolomics plays an important role in the screening of tumour biomarkers. A large number of studies have found potential biomarkers of gastric cancer, colorectal cancer, oesophageal cancer, liver cancer, ovarian cancer and other malignant tumours in blood, urine, tissue and other samples through metabolomics.[@CIT0034]--[@CIT0037] In this study, we found that TG (54:2), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methylalanine, sulfite, CL (63:4), PE-NMe (40:5), TG (53:4), retinol, 3-hydroxysterol, tetradecanoic acid, MG (21:0/0:0/0:0), tridecanoic acid, myristate glycine and octacosanoic acid have good diagnostic ability for gastric cancer metastasis and are potential independent risk factors for gastric cancer patients with peritoneal metastasis.

Metabonomics is a hot topic in recent years. It has been reported that glucose metabolism plays a key role in the growth of gastric cancer.[@CIT0038] However, we found that some lipid metabolites play a key role in peritoneal metastasis of gastric cancer, which may be caused by different pathological processes of gastric cancer. Sulfite is mainly produced from the metabolism of sulfur-containing amino acids (cysteine, methionine) in the human body.[@CIT0039] Current research shows that the level of homocysteine in the sera of patients with oesophageal cancer, gastric cancer, colorectal cancer and other malignant tumours is significantly increased. Sulfite was found to have an antitumour effect by affecting cell cycle arrest, apoptosis, invasion and colony formation in SH-SY5Y tumour cells.[@CIT0040] Xu et al[@CIT0041] used Mendel randomization to analyse 27 case--control studies on the relationship between the level of blood homocysteine and the risk of gastric cancer and proved that the level of blood homocysteine had a significant impact on the risk of gastric cancer. An increase in sulfite content in peritoneal lavage fluid may indicate an increase in homocysteine levels, which is consistent with previous research results.

G3P is an important metabolite of glycolysis and the pentose phosphate pathway.[@CIT0042] Glycolysis is the main energy source of tumour cells.[@CIT0043],[@CIT0044] The pentose phosphate pathway not only provides 5-ribonucleic acid for the rapid proliferation of tumour cells; in addition, the p53 protein has been reported to inhibit the pentose phosphate pathway by binding glucose-6-phosphate dehydrogenase. In tumour cells, p53 is mutated, enhancing the pentose phosphate pathway.[@CIT0045] Studies have shown that G3P plays an important role in tumour cell survival, tumour angiogenesis, tumour cell gene expression regulation and mRNA posttranscriptional regulation.[@CIT0046]

Lipid metabolism plays an important role in cancer.[@CIT0047] TG (54:2), PE-NMe, Cl (63:4), and TG (53:4) are triglycerides. MG (21:0/0:0/0:0:0:0) belongs to the glycerol monoester family. Myristate glycine, tridecanoic acid, octadecanoic acid, 3-methylpropionic acid and tetradecanoic acid are fatty acids. Dodecanol is a fatty alcohol in body fluids. It has been proven that the consumption of lipids and the levels of lipid metabolites are increased in gastric cancer, while the plasma levels of lipids are decreased in gastric cancer.[@CIT0048],[@CIT0049] Fatty acids can be used as a diagnostic marker of gastric cancer.[@CIT0050] In this study, we found that an increase in these lipid metabolites may indicate that lipid metabolism in the peritoneal environment in gastric cancer with peritoneal metastasis has changed significantly.

Amino acid metabolism and cholesterol metabolism play an important role in the occurrence and development of cancer. Glutamyl alanine is a naturally occurring dipeptide composed of glutamate and alanine. α-Aminobutyric acid is a nonessential amino acid mainly in the cytoplasm that is mainly produced from the catabolism of methionine, threonine and serine. 3-Hydroxysterol is the intermediate of cholesterol biosynthesis. Some studies showed that the levels of serum cholesterol and low-density lipoprotein were lower in patients with gastric cancer metastasis than in normal controls.[@CIT0051] Retinal, also known as vitamin A aldehyde, is a derivative of retinol after its oxidation. Retinol can be irreversibly oxidized to retinoic acid, which is involved in the regulation of some cellular functions, such as cell growth, proliferation and differentiation. The relationship between retinol intake and blood retinol concentration and the risk of gastric cancer were shown to be controversial in past case-control and cohort studies. Some studies have shown that retinol can reduce the risk of gastric cancer, while others have not found this relationship. A meta-analysis[@CIT0052] of 31 studies showed a slight negative correlation between retinol intake (with RR = 0.94, 95% CI: 0.87--1.03) or blood retinol level (with RR = 0.87, 95% CI: 0.73--1.05) and the risk of gastric cancer by comparing the highest and lowest intervals of the blood retinol level. Subgroup analysis showed a slight negative correlation between serum retinol level and gastric cancer risk in only Western countries.

To the best of our knowledge, this is the first study to identify the diagnostic role of metabolites in gastric cancer metastasis. Through our work, we can better help in the search for new methods to detect gastric cancer metastasis. However, the in-depth molecular mechanism has not been fully explored. In the future, we will continue to explore the molecular mechanism of metabolites in vitro and in vivo.

Conclusion {#S0005}
==========

In this study, we discovered the role of metabolites in peritoneal metastasis of gastric cancer. TG (54:2), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methylalanine, sulfite, CL (63:4), PE-NMe (40:5), TG (54:2), TG (53:4), retinol, 3-hydroxysterol, tetradecanoic acid, MG (21:0/0:0/0:0), tridecanoic acid, myristate glycine and octacosanoic acid have good diagnostic ability and are potential markers of peritoneal metastasis in gastric cancer. In the future, we will continue to explore the specific molecular mechanism of these metabolites in peritoneal metastasis of gastric cancer.
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